Overall, the clinically relevant results obtained from the MONALEESA-2 trial suggest that ribociclib in combination with other aromatase inhibitors such as letrozole can be successfully used in the treatment of advanced HR+/HER2− breast cancer in a broad population. This evidence concerns the gene HR and breast cancer.